Edinburgh Research Explorer

SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout

Research output: Contribution to journalArticle

  • James Floyd
  • Colin Na Palmer
  • Ivana Kolcic
  • Ozren Polasek
  • Juergen Graessler
  • Anthony Marinaki
  • Xinhua Shu
  • Branka Janicijevic
  • Nina Smolej-Narancic
  • Joanne Morgan
  • Susan Campbell
  • Zrinka Biloglav
  • Lovorka Barac-Lauc
  • Marijana Pericic
  • Irena Martinovic Klaric
  • Tatjana Skaric-Juric
  • William A. Richardson
  • Charley H. Kimber
  • Louise A. Donnelly
  • Lynette D. Fairbanks
  • Martin Aringer
  • Pavao Rudan

Related Edinburgh Organisations

Original languageEnglish
Pages (from-to)437-442
Number of pages6
JournalNature Genetics
Issue number4
Publication statusPublished - Apr 2008


Uric acid is the end product of purine metabolism in humans and great apes, which have lost hepatic uricase activity, leading to uniquely high serum uric acid concentrations (200 500 mu M) compared with other mammals (3-120 mu M)(1). About 70% of daily urate disposal occurs via the kidneys, and in 5-25% of the human population, impaired renal excretion leads to hyperuricemia(2). About 10% of people with hyperuricemia develop gout, an inflammatory arthritis that results from deposition of monosodium urate crystals in the joint. We have identified genetic variants within a transporter gene, SLC2A9, that explain 1.7-5.3% of the variance in serum uric acid concentrations, following a genome-wide association scan in a Croatian population sample. SLC2A9 variants were also associated with low fractional excretion of uric acid and/or gout in UK, Croatian and German population samples. SLC2A9 is a known fructose transporter(3), and we now show that it has strong uric acid transport activity in Xenopus laevis oocytes.

ID: 3341971